查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1877443

胎盘干细胞疗法市场：依疗法类型、细胞类型、最终用户、应用、国家和地区划分－全球产业分析、市场规模、市场份额及2025-2032年预测

Placental Stem Cell Therapy Market, By Therapy Type, By Cell Type, By End-user, By Application, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 355 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年胎盘干细胞疗法市场规模为 4.55 亿美元，从 2025 年到 2032 年将以 18.5% 的复合年增长率成长。

胎盘干细胞疗法利用胎盘来源的干细胞来治疗神经系统疾病及其他疾病。市场的一个关键趋势是日益重视再生医学，强调干细胞修復或取代受损神经元的能力，并满足神经系统疾病领域尚未满足的医疗需求。生物技术和干细胞研究的进步正在加速市场成长。然而，监管方面的挑战仍然是一大障碍，因为严格的审批流程可能会延迟产品上市并增加研发成本。此外，疗法的高昂成本限制了其可及性，从而限制了患者的覆盖范围和整体市场扩张。

胎盘干细胞疗法市场—市场动态

技术进步与创新研究推动市场成长

技术进步和创新研究是胎盘干细胞治疗市场成长的关键驱动力。尖端技术改进了干细胞的分离、处理和应用，从而提高了治疗效率和安全性。例如，2023年11月，新加坡-麻省理工学院科研联盟（SMART）旗下「个人化医疗製造关键分析」（CAMP）跨学科研究小组的研究人员，与新加坡科技研究局（ASTAR）生物加工技术研究院（BTI）和新加坡国立大学医疗系统（NUHS）合作，开发了一种直接从纯骨髓穿刺液中提取了间质干液（MSCs）的过程，从而简化了间质干液中提取间质干液（MSCs）。这充分体现了研究突破如何推动市场成长。

胎盘干细胞疗法市场区隔分析：

全球市场按治疗类型、细胞类型、最终用户、应用和地区进行细分。

治疗类型主要分为两大类：异体疗法和自体疗法。异体疗法因其「即用型」优势而成为重要组成部分。这些源自捐赠者的细胞产品可以冷冻保存并立即使用，使其成为需要快速介入的紧急神经系统疾病治疗的理想选择。这种操作优势省去了患者特异性（自体）细胞采集所需的时间和费用。全球监管重点也支持这一转变；2023年，世界卫生组织批准了更新的人类细胞和组织疗法全球原则，加强了成员国之间的品质、可追溯性和安全标准，并允许在临床环境中更广泛地应用异体细胞产品。此外，各国再生医学政策正在加速其规模化应用；例如，日本药品和医疗器材管理局（PMDA）在2022年至2024年间批准了20多项新的细胞和组织疗法试验，其中许多试验采用了异体细胞库系统来缩短生产时间。这些临床和监管因素使异体胎盘干细胞疗法处于战略地位，有助于市场成长。

从终端使用者角度来看，学术和研究机构在胎盘干细胞疗法的开发中发挥着至关重要的作用。他们的工作通常着重于了解胎盘来源间质干细胞（MSCs）的生物学特性、安全性和治疗潜力，以及製定良好生产规范（GMP）方案和在神经系统模型中评估其临床前疗效。一项发表于2024年《生物科学前沿》（Frontiers in Bioscience）的研究发现，人类胎盘来源的MSCs透过减少发炎和神经元凋亡，显着改善了缺氧缺血性脑病大鼠模型的神经系统预后。

胎盘干细胞疗法市场—地域洞察

北美在胎盘干细胞疗法市场占据显着份额。该地区对胎盘干细胞治疗神经系统疾病潜力的认识不断提高，推动了该疗法的应用。患者对神经系统疾病替代疗法的兴趣日益浓厚，加上疗法研发的进步，共同促进了市场成长。学术机构、医疗服务提供者和生物技术公司之间的合作，促进了专业设施的建立，提高了治疗的可及性，并使胎盘干细胞疗法得以应用于神经系统疾病的临床治疗。

美国胎盘干细胞疗法市场—国家概况

美国在胎盘干细胞疗法治疗神经系统疾病市场中扮演着举足轻重的角色，这主要得益于阿兹海默症和帕金森氏症等与年龄相关的疾病日益普遍。预计到2050年，美国65岁以上人口中将有1,300万人患有阿兹海默症，高于2025年的约720万人。 2024年，近1,200万美国人为失智症患者提供无偿照顾，凸显了有效疗法的迫切需求。此外，近100万美国人患有帕金森氏症，且罹病风险随年龄增加而急剧增加。这些数据表明，人们对创新治疗方案的需求日益增长，胎盘干细胞疗法已成为美国治疗神经系统疾病的重要手段。

胎盘干细胞疗法市场－竞争格局：

胎盘干细胞疗法市场集中度适中，少数几家关键企业引领创新并拓展全球业务。赛默飞世尔科技公司（Thermo Fisher Scientific, Inc.）、Cell Applications, Inc.、Bio-Techne 和 Cellular Engineering Technologies 等公司是专注于开髮用于治疗神经系统疾病和其他退化性疾病的先进干细胞疗法的领先企业。这些公司透过开发新的细胞分离、储存和递送技术来提高安全性、有效性和患者疗效，从而展开竞争。例如，Pluristem Therapeutics 于 2024 年 2 月宣布与美国一家生物製药公司建立策略合作伙伴关係，以推进胎盘来源间质干细胞治疗缺血性中风的临床试验，并迅速进入市场。持续的研发投入、与学术机构的合作以及促进产品商业化的监管审批，都有助于塑造市场竞争格局。为了满足全球对再生疗法日益增长的需求，企业扩张策略包括加强生产能力和进入新兴市场。

目录

第一章：胎盘干细胞疗法市集概览

  • 研究范围
  • 市场估算年份

第二章：执行概要

  • 市集
    • 胎盘干细胞疗法市场概览（按疗法类型划分）
    • 胎盘干细胞疗法市场概览（按细胞类型划分）
    • 胎盘干细胞疗法市场按最终用户分類的概况
    • 胎盘干细胞疗法市场按应用领域分類的概览
    • 各国胎盘干细胞疗法市场概况
    • 胎盘干细胞疗法市场区域概览
  • 竞争洞察

第三章：胎盘干细胞疗法主要市场趋势

  • 胎盘干细胞疗法市场驱动因素
    • 市场驱动因素的影响分析
  • 胎盘干细胞疗法市场限制因素
    • 市场限制因素的影响分析
  • 胎盘干细胞疗法市场机会
  • 胎盘干细胞疗法市场未来趋势

第四章：胎盘干细胞疗法产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景分析
  • 规范架构分析

第五章：胎盘干细胞疗法市场：地缘政治紧张局势升级的影响

  • 新冠疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：胎盘干细胞疗法市场概况

  • 胎盘干细胞疗法市占率分析（2024年）
  • 主要製造商细分数据
    • 知名球员分析
    • 新兴参与者分析

第七章：胎盘干细胞疗法市场－依疗法类型划分

  • 概述
    • 按治疗类型分類的细分市场份额分析
    • 异体疗法
    • 自体疗法

第八章：胎盘干细胞疗法市场－以细胞类型划分

  • 概述
    • 按细胞类型分類的细分市场份额分析
    • 间质干细胞（MSCs）
    • 内皮祖细胞（EPCs）
    • 脐带间质干细胞
    • 造血干细胞（HSCs）
    • 胎盘来源的间质干细胞
    • 混合/共培养干细胞

第九章：胎盘干细胞疗法市场－以最终用户划分

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 医院和专科诊所
    • 研究与学术机构
    • 生物製药公司
    • 合约研究组织（CRO）

第十章：胎盘干细胞疗法市场－依应用领域划分

  • 概述
    • 按细胞类型分類的细分市场份额分析
    • 血液系统恶性肿瘤和疾病
    • 代谢紊乱
    • 神经系统疾病
    • 先天性免疫缺乏疾病
    • 其他的

第十一章：胎盘干细胞疗法市场－以地域划分

  • 介绍
    • 按地域分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美胎盘干细胞疗法主要生产商
    • 北美市场规模及预测（按国家/地区划分）
    • 北美市场规模及预测（按治疗类型划分）
    • 北美市场规模及预测（按电池类型划分）
    • 北美市场规模及预测（依最终用户划分）
    • 北美市场规模及预测（按应用划分）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲胎盘干细胞疗法主要生产商
    • 欧洲市场规模及预测（按国家/地区划分）
    • 欧洲市场规模及预测（依治疗类型划分）
    • 欧洲市场规模及预测（按电池类型划分）
    • 欧洲市场规模及预测（依最终用户划分）
    • 欧洲市场规模及预测（按应用领域划分）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区
    • 概述
    • 亚太地区胎盘干细胞疗法主要生产商
    • 亚太市场规模及预测（依国家/地区划分）
    • 亚太地区市场规模及预测（依治疗类型划分）
    • 亚太地区市场规模及预测（依细胞类型划分）
    • 亚太市场规模及预测（依最终用户划分）
    • 亚太市场规模及预测（按应用划分）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲胎盘干细胞疗法主要生产商
    • 拉丁美洲市场规模及预测（按国家/地区划分）
    • 拉丁美洲市场规模及预测（按治疗类型划分）
    • 拉丁美洲市场规模及预测（按细胞类型划分）
    • 拉丁美洲市场规模及预测（按最终用户划分）
    • 拉丁美洲市场规模及预测（按应用划分）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲（MEA）
    • 概述
    • 中东和非洲胎盘干细胞疗法主要生产商
    • MEA市场规模及预测（依国家/地区划分）
    • MEA市场规模及预测（依治疗类型划分）
    • MEA市场规模及预测（依细胞类型划分）
    • MEA市场规模及预测（依最终用户划分）
    • MEA市场规模及预测（依应用划分）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • 中东和非洲其他地区

第十二章：主要供应商分析－胎盘干细胞治疗产业

  • 竞争基准化分析
    • Competitive Dashboard
    • Competitive Positioning
  • 公司简介
    • Thermo Fisher Scientific, Inc
    • Cell Applications, Inc.
    • Bio-Techne
    • Cellular Engineering Technologies
    • AlloSource
    • STEMCELL Technologies, Inc.
    • PromoCell GmbH
    • Takara Holdings, Inc.
    • Lonza
    • Merck KGaA
    • Sartorius AG (CellGenix GmbH)
    • ATCC
    • AcceGen
    • Mesoblast Ltd
    • Others

第十三章：360度AnalystView

第十四章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5748

The Placental Stem Cell Therapy Market size was valued at US$ 455 Million in 2024, expanding at a CAGR of 18.5% from 2025 to 2032.

Placental Stem Cell Therapy leverages placental-derived stem cells to treat neurological and other disorders. A key market trend is the growing emphasis on regenerative medicine, highlighting the ability of stem cells to repair or replace damaged neurons and address unmet medical needs in neurological conditions. Advances in biotechnology and stem cell research are accelerating market growth. However, regulatory challenges remain a significant barrier, as stringent approval processes can delay market entry and increase development costs. Additionally, the high cost of therapies limits accessibility, constraining patient reach and overall market expansion.

Placental Stem Cell Therapy Market- Market Dynamics

Technological Advances and Innovative Research Drive Market Growth

Technological advancements and innovative research are critical drivers of growth in the placental stem cell therapy market. Cutting-edge technologies improve the isolation, processing, and application of stem cells, thereby increasing treatment efficiency and safety. For instance, in November 2023, researchers from the Critical Analytics for Manufacturing Personalized Medicine (CAMP) Interdisciplinary Research Group (IRG) of Singapore-MIT Alliance for Research and Technology (SMART), in collaboration with ASTAR's Bioprocessing Technology Institute (BTI) and the National University Health System (NUHS), developed a technology to extract mesenchymal stem cells (MSCs) directly from pure bone marrow aspirate, streamlining. This demonstrates how research breakthroughs drive market growth.

Placental Stem Cell Therapy Market- Segmentation Analysis:

The worldwide market is segmented on the basis of Therapy Type, Cell Type, End-user, Application, and Region.

The therapy type segment is primarily divided into two groups Allogeneic Therapy and Autologous Therapy. Allogeneic therapies are an important segment due to their "off-the-shelf" availability. These donor-derived cell products can be cryopreserved and used right away, making them ideal for emergency neurological care where prompt intervention is required. This operational advantage eliminates the time and expense associated with patient-specific (autologous) cell harvesting. This shift is also being supported by global regulatory focuses; in 2023, the World Health Organization endorsed updated global principles for human cell and tissue therapies, strengthening quality, traceability, and safety standards across member states and allowing for broader deployment of allogeneic cell products in clinical settings. Furthermore, national regenerative-medicine policies are accelerating scale-up; for example, Japan's PMDA approved over 20 new cell- and tissue-based therapy trials between 2022 and 2024, many of which used allogeneic cell banking systems to reduce manufacturing time. These clinical and regulatory factors place allogeneic placental stem cell therapies in a strategic position to contribute to market growth.

Based on End user segment, Academic and research institutions play critical roles in the development of placental stem cell therapies. Their work frequently focuses on understanding the biology, safety, and therapeutic potential of placental-derived mesenchymal stromal cells (MSCs), as well as developing good manufacturing practices (GMP) protocols and preclinical efficacy in neurological models. A 2024 study published in Frontiers in Bioscience by a university-affiliated research center found that human placenta-derived MSCs significantly improved neurological outcomes in a rat model of hypoxic-ischemic encephalopathy by reducing inflammation and neuronal apoptosis.

Placental Stem Cell Therapy Market- Geographical Insights

North America has a significant market share for placental stem cell therapy. Adoption in the region is being driven by a growing awareness of placental stem cells' therapeutic potential for neurological conditions. Increased patient interest in alternative treatments for neurological disorders, combined with advances in therapy development, is driving market growth. Collaborations among academic institutions, healthcare providers, and biotechnology companies have facilitated the establishment of specialized facilities, increased accessibility and allowing clinical applications of placental stem cell therapies for neurological conditions.

United States Placental Stem Cell Therapy Market- Country Insights

The United States plays a pivotal role in generating revenue within the placental stem cell therapy market for neurological disorders, driven by the increasing prevalence of age-associated conditions such as Alzheimer's and Parkinson's disease. By 2050, it is projected that 13 million Americans aged 65 and older will be living with Alzheimer's, up from approximately 7.2 million in 2025. In 2024, nearly 12 million Americans provided unpaid care for individuals suffering from dementia, highlighting the urgent need for effective therapies. Additionally, nearly one million Americans are affected by Parkinson's disease, with risk increasing sharply with age. These statistics underscore the rising demand for innovative treatment options, positioning placental stem cell therapies as a significant therapeutic approach for managing neurological disorders in the U.S.

Placental Stem Cell Therapy Market- Competitive Landscape:

The placental stem cell therapy market is moderately concentrated, with a few key players driving innovation and expanding their global presence. Thermo Fisher Scientific, Inc., Cell Applications, Inc., Bio-Techne, and Cellular Engineering Technologies are among the leading companies that specialize in developing advanced stem cell therapies for neurological and other degenerative disorders. These companies compete by developing new cell isolation, storage, and delivery technologies that improve safety, efficacy, and patient outcomes. For example, Pluristem Therapeutics announced a strategic partnership with a biopharmaceutical company in the United States in February 2024 to advance clinical trials of placental-derived mesenchymal stem cells for ischemic stroke treatment, and to enter the market quickly. Continuous R&D investments, collaborations with academic institutions, and regulatory approvals that facilitate product commercialization all help to shape market competition. To meet the increasing global demand for regenerative therapies, expansion strategies include strengthening manufacturing capabilities and entering emerging markets.

Recent Developments:

In December 2024, Mesoblast Limited has announced that Ryoncil (remestemcel-L) has received FDA approval as the first mesenchymal stromal cell (MSC) therapy in the United States. Ryoncil is now the only MSC therapy approved in the United States, as well as the first treatment for steroid-resistant acute graft-versus-host disease (SR-aGvHD) in children as young as two months old, including adolescents and teenagers. Dr. Joanne Kurtzberg, a leading transplant physician at Duke University Medical Center, emphasized the importance of this approval, stating that Ryoncil provides a life-saving option for children with this severe condition, giving hope to both patients and their families.

In October, 2024, Aspen Neuroscience, Inc. has announced the expansion of its San Diego operations with a new 22,000 square foot facility dedicated to the GMP manufacturing of induced pluripotent stem cell (iPSC)-based therapies. This facility, located near the company's headquarters, will manufacture ANPD001, an iPSC-derived cell therapy for Parkinson's disease, as part of the ASPIRO trial. The expansion includes ISO-certified manufacturing suites, quality control labs, and more room for future growth and automation. Aspen is also working to industrialize autologous cell therapy manufacturing to improve throughput and streamline production processes.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PLACENTAL STEM CELL THERAPY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Thermo Fisher Scientific, Inc
  • Cell Applications, Inc.
  • Bio-Techne
  • Cellular Engineering Technologies
  • AlloSource
  • STEMCELL Technologies, Inc.
  • PromoCell GmbH
  • Takara Holdings, Inc.
  • Lonza
  • Merck KGaA
  • Sartorius AG (CellGenix GmbH)
  • ATCC
  • AcceGen
  • Mesoblast Ltd
  • Others

GLOBAL PLACENTAL STEM CELL THERAPY MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Allogeneic Therapy
  • Autologous Therapy

GLOBAL PLACENTAL STEM CELL THERAPY MARKET, BY CELL TYPE- MARKET ANALYSIS, 2019 - 2032

  • Mesenchymal Stem Cells (MSCs)
  • Endothelial Progenitor Cells (EPCs)
  • Umbilical-Derived MSCs
  • Hematopoietic Stem Cells (HSCs)
  • Placental-Derived MSCs
  • Mixed/Co-Culture Stem Cells

GLOBAL PLACENTAL STEM CELL THERAPY MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals & Specialty Clinics
  • Research & Academic Institutes
  • Biopharmaceutical Companies
  • Contract Research Organizations (CROs)

GLOBAL PLACENTAL STEM CELL THERAPY MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Hematologic Malignancies and Disorders
  • Metabolic Disorders
  • Neurological Disorders
  • Congenital Immunodeficiency Disorders
  • Others

GLOBAL PLACENTAL STEM CELL THERAPY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Placental Stem Cell Therapy Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Placental Stem Cell Therapy Market Snippet by Therapy Type
    • 2.1.2. Placental Stem Cell Therapy Market Snippet by Cell Type
    • 2.1.3. Placental Stem Cell Therapy Market Snippet by End-user
    • 2.1.4. Placental Stem Cell Therapy Market Snippet by Application
    • 2.1.5. Placental Stem Cell Therapy Market Snippet by Country
    • 2.1.6. Placental Stem Cell Therapy Market Snippet by Region
  • 2.2. Competitive Insights

3. Placental Stem Cell Therapy Key Market Trends

  • 3.1. Placental Stem Cell Therapy Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Placental Stem Cell Therapy Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Placental Stem Cell Therapy Market Opportunities
  • 3.4. Placental Stem Cell Therapy Market Future Trends

4. Placental Stem Cell Therapy Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Placental Stem Cell Therapy Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Placental Stem Cell Therapy Market Landscape

  • 6.1. Placental Stem Cell Therapy Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Placental Stem Cell Therapy Market - By Therapy Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapy Type, 2024 & 2032 (%)
    • 7.1.2. Allogeneic Therapy
    • 7.1.3. Autologous Therapy

8. Placental Stem Cell Therapy Market - By Cell Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Cell Type, 2024 & 2032 (%)
    • 8.1.2. Mesenchymal Stem Cells (MSCs)
    • 8.1.3. Endothelial Progenitor Cells (EPCs)
    • 8.1.4. Umbilical-Derived MSCs
    • 8.1.5. Hematopoietic Stem Cells (HSCs)
    • 8.1.6. Placental-Derived MSCs
    • 8.1.7. Mixed/Co-Culture Stem Cells

9. Placental Stem Cell Therapy Market - By End-user

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-user, 2024 & 2032 (%)
    • 9.1.2. Hospitals & Specialty Clinics
    • 9.1.3. Research & Academic Institutes
    • 9.1.4. Biopharmaceutical Companies
    • 9.1.5. Contract Research Organizations (CROs)

10. Placental Stem Cell Therapy Market - By Application

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Cell Type, 2024 & 2032 (%)
    • 10.1.2. Hematologic Malignancies and Disorders
    • 10.1.3. Metabolic Disorders
    • 10.1.4. Neurological Disorders
    • 10.1.5. Congenital Immunodeficiency Disorders
    • 10.1.6. Others

11. Placental Stem Cell Therapy Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Placental Stem Cell Therapy Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Placental Stem Cell Therapy Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Placental Stem Cell Therapy Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Placental Stem Cell Therapy Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Placental Stem Cell Therapy Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Cell Type, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Placental Stem Cell Therapy Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Thermo Fisher Scientific, Inc
    • 12.2.2. Cell Applications, Inc.
    • 12.2.3. Bio-Techne
    • 12.2.4. Cellular Engineering Technologies
    • 12.2.5. AlloSource
    • 12.2.6. STEMCELL Technologies, Inc.
    • 12.2.7. PromoCell GmbH
    • 12.2.8. Takara Holdings, Inc.
    • 12.2.9. Lonza
    • 12.2.10. Merck KGaA
    • 12.2.11. Sartorius AG (CellGenix GmbH)
    • 12.2.12. ATCC
    • 12.2.13. AcceGen
    • 12.2.14. Mesoblast Ltd
    • 12.2.15. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us